BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications

BEIJING - BioDuro and AstraZeneca announced today that they have expanded their
research collaboration to optimize discovery research for Respiratory and
Inflammation indications.

BioDuro will provide integrated research services in the areas of
discovery chemistry, discovery biology, ADMET*, and DMPK** services, to help
enhance internal drug discovery and shorten development timelines.

“After a successful collaboration involving discovery chemistry, ADMET,
and DMPK, AstraZeneca has expanded its collaboration with BioDuro to leverage
the strengths of its team to help develop new therapeutics,” said Lena
Martensson Director of Strategic Planning and Business Development.

“BioDuro is pleased to build upon this existing collaboration and work
closely with the experienced team at AstraZeneca to develop new clinical
compounds for Respiratory and Inflammation indications. This partnership
demonstrates the strength of our innovation, quality, and our fully
integrated R&D service platform,” commented John Oyler, Chief Executive
Officer and co-founder of BioDuro LLC.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the
research, development, manufacturing and marketing of meaningful prescription
medicines and supplier for healthcare services. AstraZeneca is one of the
world’s leading pharmaceutical companies with healthcare sales of US$31.6
billion and is a leader in gastrointestinal, cardiovascular, neuroscience,
respiratory, oncology and infectious disease medicines. For more information
about AstraZeneca, please visit: www.astrazeneca.com

About BioDuro

BioDuro is a US-based, fully-integrated, end-to-end global life science
outsourcing services company with a team of 580 in Beijing, China. BioDuro
combines western pharmaceutical company quality and professionalism, with
entrepreneurial, innovative biotech culture, to leverage its talented,
hard-working Chinese scientists. BioDuro’s clients are over 40 pharmaceutical
and biotechnology companies, including 10 of the top-12. BioDuro’s services
span the entire range of drug discovery and development, from discovery
chemistry, discovery biology, early ADMET, DMPK, through pharmacology and
drug safety and evaluation.

*ADMET: Absorption, Distribution, Metabolism, Excretion, and Toxicity
**DMPK: Drug Metabolism and Pharmacokinetics

Source: BioDuro, LLC

Ryan Brady of BioDuro LLC, +1-317-331-3029, ryan.brady at bioduro.com